[HTML][HTML] Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
H Mizuta, K Okada, M Araki, J Adachi… - Nature …, 2021 - nature.com
ALK gene rearrangement was observed in 3%–5% of non-small cell lung cancer patients,
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
H Mizuta, K Okada, M Araki, J Adachi… - Nature …, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p>< jats: italic> ALK</jats: italic> gene
rearrangement was observed in 3%–5% of non-small cell lung cancer patients, and multiple …
rearrangement was observed in 3%–5% of non-small cell lung cancer patients, and multiple …
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
H Mizuta, K Okada, M Araki, J Adachi… - Nature …, 2021 - keio.elsevierpure.com
抄録 ALK gene rearrangement was observed in 3%–5% of non-small cell lung cancer
patients, and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used …
patients, and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used …
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
H Mizuta, K Okada, M Araki, J Adachi… - Nature …, 2021 - europepmc.org
ALK gene rearrangement was observed in 3%–5% of non-small cell lung cancer patients,
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
[HTML][HTML] Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
H Mizuta, K Okada, M Araki, J Adachi… - Nature …, 2021 - ncbi.nlm.nih.gov
ALK gene rearrangement was observed in 3%–5% of non-small cell lung cancer patients,
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
H Mizuta, K Okada, M Araki, J Adachi… - Nature …, 2021 - ui.adsabs.harvard.edu
ALK gene rearrangement was observed in 3%-5% of non-small cell lung cancer patients,
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
H Mizuta, K Okada, M Araki, J Adachi… - Nature …, 2021 - ideas.repec.org
ALK gene rearrangement was observed in 3%–5% of non-small cell lung cancer patients,
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
H Mizuta, K Okada, M Araki, J Adachi… - Nature …, 2021 - search.ebscohost.com
ALK gene rearrangement was observed in 3%–5% of non-small cell lung cancer patients,
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
H Mizuta, K Okada, M Araki, J Adachi… - Nature …, 2021 - econpapers.repec.org
ALK gene rearrangement was observed in 3%–5% of non-small cell lung cancer patients,
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
H Mizuta, K Okada, M Araki, J Adachi… - Nature …, 2021 - hero.epa.gov
ALK gene rearrangement was observed in 3%-5% of non-small cell lung cancer patients,
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …
and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple …